Highlight

CLINICAL RESEARCH 2007, May 24   Parexel: The Cap provides its support     Through the words of its vice president in charge of economic development and employment, Catherine Coutelle, Greater Poitiers (the CAP) is throwing its weight behind the clinical research center Parexel, the conformity of some of whose studies has not been attested by the Afssaps. “The local press recently evoked the momentary difficulties encountered by the clinical research center Parexel, which is to be found in the Gibauderie zone of Poitiers. Strongly involved in the bringing into being of the Biopole of Greater Poitiers, it is with the closest attention that I have been following the evolution of all those belonging to the pole. The Poitiers-based laboratory Parexel, a subsidiary of the American group Parexel International, has been deemed by the French agency of sanitary safety for health products (Afssaps) not to have been functioning, at the time of an inspection that took place in 2006, in conformity with the relevant international requirements. The laboratory conducts analyses on behalf of the pharmaceutical industry. The procedural imperfections that were noticed have to do with assay techniques in the animal. Safety trials must quite obviously be conducted in accordance with the rules of good practice and in full respect of rigorous methods of analysis. That is why the Afssaps performs regular inspections. I have spoken with Mr. Bertoye, who heads the clinical trials and safety inspection department at the Afssaps. Parexel has already organized a number of corrective actions and is presently pursuing its action plan. Fully aware of the difficulties entailed by its decision in terms of market loss and impact on studies conducted in the interest of public health, Afssaps is closely following the company at this difficult moment. A new expert appraisal is underway, and quite soon, its conclusions will have been drawn. In the Biopole framework, the CAP has unfailingly supported Paraxel’s research activities and accompanied the Poitiers-based laboratory as it aspires to become the group’s European center of bioanalysis. In these times of difficulty for Parexel, in the name of the CAP I wish to address a message of support to the 45 employees on a site of which the scientific competence, the level of qualification and the quality of whose investigations constitute a decisive “plus” in worldwide competition; I likewise express my support to the group’s local management; we have always maintained excellent relations, and we shall be meeting again over the coming days. I haven’t the slightest doubt that they will do all they can in order to recover the accreditation necessary to pursuit of their activity, and that they will be drawing upon the skills and reliability of their personnel.” The Biopole en masse at Eurobio 2008 Read ...   Water information days (September 23 – September 25) Read ...   The rose and its genetic transformation Read ...   Christian Huyghe aims for “excellence” read...   Creating “medical branches” read...   A neuro-cardio-vascular pole is taking root read...   Valagro on the horticulture market read...   ERM, the winning spin-off read...   GMOs under debate in Poitiers read...   Isabelle Cameleyre, new representative read...   Cystic fibrosis: The molecule of hope read...   Irfaq, a manufacturer of innovations read...   CHU: State-of-the-art quality read...   Soil organic matter under examination read...   Parexel: The Cap provides its support read...   Philippe Michonneau: “The Biopole, fertile soil” read...   Painless monitoring of hepatitis read...   The Biopole structured as an association read...   Futuramat steps up the pace read...   Technova, or life in 3D read...   B Braun burnishes its image read...   Proteomics platform: The CHU strides ahead read...   The three missions of the University Botanical Garden read...   Clinsight in the big leagues read...   Natural energies for an autonomous building read...   Aster-Cephac turns into SGS Cephac read...   The previously unseen heart read...   BIOalternatives diversifies its markets read...   Two Poitiers-based projects awarded read...   IUT pores over biofuels read...   Poitiers, the biotechnology capital read...   PAREXEL wagers on the human factor read...   Saunier and associates wish to diversify read...   Biocydex and BioXtract move forward hand in hand read...   The grass of champions read...   Ianesco steadfastly believes in its future read...   A tumorotheque, what is the purpose it serves? read...   TechnAvOx has turned the corner read...   Larime is aiming for 40 beds in Poitiers read...   Poitiers is out to promote its research read...   A true Biopole milestone read...   A regional cancerology pole in the pipeline for 2007 read...   Nobel prize winners in Poitiers read...   A platform offering numerous advantages read...   @rtMolecule fashions in its own way read...   It’s plastic, it’s fantastic read...   The Poitiers hospital (CHU) stakes its claim read...   BIOalternatives exports its know-how read...   The physiological and computer science engineering program turns 30 read...   The Biopole takes center stage at Investiga read...           Legal mentions